| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5597257 | The Annals of Thoracic Surgery | 2017 | 8 Pages |
Abstract
EndMT contributes to cardiac fibrosis in hypertrophied hearts. VEGF treatment inhibits EndMT and prevents the deposition of collagen that leads to myocardial stiffness through TGF-β/SMAD-dependent activation. This presents a therapeutic opportunity to prevent diastolic failure and preserve cardiac function in pressure-loaded hearts.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Ben M.-W. MD, Alejandra MD, Dimitrios BS, Robert MD, PhD, Pedro J. MD, Ingeborg MD,